Loading the latest PSX data…
Loading the latest PSX data…
GlaxoSmithKline Consumer Healthcare
−3.88 (−3.13%) today
Market closed, last update Nov 17, 2026 10:07 PMThe GlaxoSmithKline Consumer Healthcare share price was Rs 120.23 (−3.13%) at the last PSX update (Nov 17, 2026 10:07 PM). GSKCH is a pharmaceuticals stock with a market value of Rs 14.1bn.
52-week range
120.005% up the range124.25
Price limits (circuit breakers)
114.8029% up the range133.42
−71.7% over 5 years
Monthly closing prices from the PSX Data Portal, since 2017.
| Measure | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Sales growth | +21.8% | +21.6% | +9.7% | – |
| Profit growth | +69.1% | +0.4% | +17.0% | – |
| EPS growth | +69.1% | +0.4% | +17.0% | – |
| Net margin | 8.8% | 6.4% | 7.7% | 7.2% |
| Measure | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|
| Sales growth | +8.5% | – | – | – |
| Profit growth | −194.9% | – | – | – |
| EPS growth | −194.9% | – | – | – |
| Net margin | -5.2% | -3.9% | 7.8% | 6.0% |
| Line item | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Sales | Rs 24.2bn | Rs 19.8bn | Rs 16.3bn | Rs 14.9bn |
| Profit after tax | Rs 2.1bn | Rs 1.3bn | Rs 1.3bn | Rs 1.1bn |
| Earnings per share (Rs) | 18.23 | 10.78 | 10.74 | 9.18 |
| Line item | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|
| Sales | Rs 6.6bn | Rs 7.1bn | Rs 7.1bn | Rs 6.1bn |
| Profit after tax | Rs -345m | Rs -279m | Rs 557m | Rs 364m |
| Earnings per share (Rs) | -2.95 | -2.39 | 4.76 | 3.11 |
| Line item | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Gross margin | 27.4% | 26.9% | 30.6% | 29.2% |
| Net margin | 8.8% | 6.4% | 7.7% | 7.2% |
| EPS growth | 69.1% | 0.4% | 17.0% | 24.2% |
| PEG | 0.19 | 66.04 | 1.40 | 1.20 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2022) EPS fell 194.9% from the same quarter a year earlier.
| Measure | GSKCH | Sector median | Reading |
|---|---|---|---|
| P/E | – | 12.2 | – |
| Dividend yield | – | 5.1% | – |
| Net margin | 8.8% | 9.4% | Below peers |
| EPS growth | +69.1% | +28.2% | Above peers |
| 1-year return | – | −14.3% | – |
Sector P/E check. At the sector's median P/E of 12.2, last year's EPS of Rs 18.23 would price GSKCH at about Rs 223.26 (+86% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for GSKCH (Graham, Lynch, DCF)GSKCH pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your GSKCH dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
10th of 18
Rs 14.1bn
EPS growth
3rd of 15
69.1%
Net margin
9th of 16
8.8%
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 106.1bn | −1.89% | 9.7 | 6.1% | −15.4% | 87 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.5bn | +0.18% | 10.6 | 4.4% | −7.6% | 81 |
| HALEONHaleon Pakistan Limited | Rs 79.8bn | −1.15% | 12.2 | 3.6% | −16.6% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.1bn | +0.89% | 12.4 | 5.4% | −14.3% | 78 |
| SEARLThe Searle Company Limited | Rs 46.6bn | −0.37% | 12.0 | – | −23.6% | 53 |
| AGPAGP Limited | Rs 43.2bn | −0.84% | 24.1 | 5.1% | −18.3% | 49 |
| HPLHoechst Pakistan Limited | Rs 38.8bn | +0.53% | 11.1 | 6.9% | −2.7% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.7bn | −0.96% | 22.8 | 1.6% | −9.0% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.4bn | −0.74% | 17.7 | – | −23.2% | 31 |
| GSKCHThis stock · GlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | −0.60% | 18.2 | – | −10.8% | 45 |
| MACTERMacter International Limited | Rs 11.7bn | −1.08% | 3.7 | – | −27.9% | 52 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +0.79% | 11.6 | – | +39.6% | 65 |
| LIVENLiven Pharma Limited | Rs 5.4bn | +10.00% | – | – | −2.3% | 15 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in GSKCH read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
GlaxoSmithKline Consumer Healthcare Pakistan Limited was incorporated in Pakistan as a public unlisted company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on March 31, 2015 principally to effect the demerger of consumer healthcare business of GlaxoSmithKline Pakistan Limited (GSK Pakistan). The Company is a subsidiary of GlaxoSmithKline Consumer Healthcare B.V. The ultimate parent of the Company is Haleon plc. The Company is engaged in manufacturing, marketing and sale of consumer healthcare products.
Where the price sits in its 52-week range
Low 120.005% of the way upHigh 124.25
Data: PSX Data Portal (Nov 17, 2026 10:07 PM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell GSKCH. Official PSX page for GSKCH